233 related articles for article (PubMed ID: 1983228)
1. 5HT3-antagonist receptors: their role in drug-induced emesis.
Dieras V; Extra JM; Le Bonniec M; Madelaine I; Espie M; Marty M
Nouv Rev Fr Hematol (1978); 1990; 32(6):449-52. PubMed ID: 1983228
[TBL] [Abstract][Full Text] [Related]
2. Emesis and anti-emesis.
Naylor RJ; Rudd JA
Cancer Surv; 1994; 21():117-35. PubMed ID: 8564988
[TBL] [Abstract][Full Text] [Related]
3. Cancer chemotherapy-induced nausea and vomiting: role of mediators, development of drugs and treatment methods.
Mahesh R; Perumal RV; Pandi PV
Pharmazie; 2005 Feb; 60(2):83-96. PubMed ID: 15739895
[TBL] [Abstract][Full Text] [Related]
4. Tropisetron (Navoban) alone and in combination with dexamethasone in the prevention of chemotherapy-induced emesis: the Nordic experience.
Sorbe BG
Semin Oncol; 1994 Oct; 21(5 Suppl 9):20-6. PubMed ID: 9113123
[TBL] [Abstract][Full Text] [Related]
5. Preliminary experience with use of a selective 5HT3 receptor antagonist (ondansetron) to prevent high dose chemotherapy induced emesis.
Parikh PM; Shah SR; Shah SC; Sheth V; Patel RA; Shah KC; Jain PK
Indian J Cancer; 1996 Mar; 33(1):17-20. PubMed ID: 9063013
[TBL] [Abstract][Full Text] [Related]
6. Prevention of chemotherapy-induced nausea and vomiting by tropisetron (Navoban) alone or in combination with other antiemetic agents.
Bruntsch U; Drechsler S; Eggert J; Gosse H; Ukena D; Imhoff W; Faerber L
Semin Oncol; 1994 Oct; 21(5 Suppl 9):7-11. PubMed ID: 9113120
[TBL] [Abstract][Full Text] [Related]
7. Development of serotonin antagonists for the control of chemotherapy-induced emesis.
Hainsworth JD
Semin Surg Oncol; 1993; 9(3):279-84. PubMed ID: 8516617
[TBL] [Abstract][Full Text] [Related]
8. Antiemetic effect of ondansetron and dexamethasone in gynecologic malignant patients receiving chemotherapy.
Pradermdee P; Manusirivithaya S; Tangjitgamol S; Thavaramara T; Sukwattana P
J Med Assoc Thai; 2006 Oct; 89 Suppl 4():S29-36. PubMed ID: 17725140
[TBL] [Abstract][Full Text] [Related]
9. 5-HT3-receptor antagonists: a review of pharmacology and clinical efficacy.
Cunningham RS
Oncol Nurs Forum; 1997 Aug; 24(7 Suppl):33-40. PubMed ID: 9282379
[TBL] [Abstract][Full Text] [Related]
10. [New developments in the treatment of nausea and vomiting caused by chemotherapy].
de Wit R; van Alphen MM
Ned Tijdschr Geneeskd; 2003 Apr; 147(15):690-4. PubMed ID: 12722531
[TBL] [Abstract][Full Text] [Related]
11. Pathogenesis-based treatment of chemotherapy-induced nausea and vomiting--two new agents.
Navari RM
J Support Oncol; 2003; 1(2):89-103. PubMed ID: 15352652
[TBL] [Abstract][Full Text] [Related]
12. A report comparing the use of tropisetron (Navoban), a 5-HT3 antagonist, with a standard antiemetic regimen of dexamethasone and metoclopramide in cisplatin-treated patients under conditions of severe emesis.
Madej G; Krzakowski M; Pawinski A; Lasota W; Rogowski W; Skoneczna I
Semin Oncol; 1994 Oct; 21(5 Suppl 9):3-6. PubMed ID: 9113119
[TBL] [Abstract][Full Text] [Related]
13. Randomized, double-blind, dose-finding study of dexamethasone in preventing acute emesis induced by anthracyclines, carboplatin, or cyclophosphamide:
Italian Group For Antiemetic Research
J Clin Oncol; 2004 Feb; 22(4):725-9. PubMed ID: 14966097
[TBL] [Abstract][Full Text] [Related]
14. 5-HT3-receptor antagonists in the control of delayed-onset emesis.
Gridelli C
Anticancer Res; 2003; 23(3C):2773-82. PubMed ID: 12926112
[TBL] [Abstract][Full Text] [Related]
15. Is there a pharmacological basis for differences in 5-HT3-receptor antagonist efficacy in refractory patients?
de Wit R; Aapro M; Blower PR
Cancer Chemother Pharmacol; 2005 Sep; 56(3):231-8. PubMed ID: 15838653
[TBL] [Abstract][Full Text] [Related]
16. Anti-emetic therapy in cancer chemotherapy: current status.
Herrstedt J; Dombernowsky P
Basic Clin Pharmacol Toxicol; 2007 Sep; 101(3):143-50. PubMed ID: 17697032
[TBL] [Abstract][Full Text] [Related]
17. [Value of 5-HT3 receptor antagonists, particularly as anti-emetic drugs].
Lechat P
Ann Pharm Fr; 1991; 49(6):307-16. PubMed ID: 1842169
[TBL] [Abstract][Full Text] [Related]
18. Use of dexamethasone with 5-HT3-receptor antagonists for chemotherapy-induced nausea and vomiting.
Perez EA
Cancer J Sci Am; 1998; 4(2):72-7. PubMed ID: 9532406
[TBL] [Abstract][Full Text] [Related]
19. Comparison of ondansetron-dexamethasone-lorazepam versus metoclopramide-dexamethasone-lorazepam in the control of cisplatin induced emesis.
Manusirivithaya S; Chareoniam V; Isariyodom P; Sungsab D
J Med Assoc Thai; 2001 Jul; 84(7):966-72. PubMed ID: 11759977
[TBL] [Abstract][Full Text] [Related]
20. Ondansetron: a specific serotonin antagonist for the prevention of chemotherapy-induced vomiting.
Kris MG
Important Adv Oncol; 1994; ():165-77. PubMed ID: 8206488
[No Abstract] [Full Text] [Related]
[Next] [New Search]